港股異動 | 海吉亞醫療早盤漲超17%,年度純利同比增長327.7%
uSMART盈立智投3月30日消息,週二港股早盤,海吉亞醫療一度漲超17%,截至10:05,漲16.15%,報55.7港元。
海吉亞醫療2020年收入14.02億元(人民幣,下同),同比增長29.1%;股東應佔溢利1.70億元,同比增長327.7%;每股基本盈利0.38元,擬派末期股息每股0.12元。
集團的毛利率由2019年度的30.4%增加至2020年度的34.2%。毛利率的提升主要是由於醫院業務收入規模迅速擴大以及成本費用攤薄效應充分體現。同時集團以腫瘤爲特色的品牌影響力以及學術能力不斷提升,收入結構進一步優化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.